Abstract Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

The cost of Eliquis can vary based on your insurance coverage, the pharmacy you use, and whether you’re eligible for cost assistance. The price of 2.5-mg and 5-mg Eliquis tablets is likely the ...

According to the manufacturer of Eliquis, in 2025, the list price for a 30-day supply of Eliquis is $606, but Medicare beneficiaries pay, on average, $54 per month. And 5 out of 10 people on ...

Apixaban: A Novel Oral Inhibitor of Factor Xa Edith Nutescu, Pharm.D., FCCP Disclosures Am J Health Syst Pharm. 2012;69 (13):1113-1126. 0 ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below ...

Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024 and so far in 2025, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new ...

Between now and 2028, Pfizer will lose patent exclusivity for Inlyta, Xeljanz, Prevnar 13, Eliquis, Ibrance, Mektovi, Xtandi, and Vyndaqel. Five of those eight products were blockbusters last year.

Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation TA275 27 February 2013 2 July 2021 Dabigatran etexilate for the prevention of stroke and systemic ...

Pharmalgen for the treatment of bee and wasp venom allergy TA246 22 February 2012 22 February 2012 Tocilizumab for the treatment of rheumatoid arthritis TA247 22 February 2012 22 February 2012 ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Specifically, BMS is taking issue with a decision to deny its rebate plan for big-selling blood thinner Eliquis (apixaban) under the 340B federal drug discount programme – which requires ...

Extended anticoagulation using reduced-dose apixaban was found to be noninferior to using full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients who had active cancer ...